Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
BM Russell, DE Avigan - International Journal of Hematology, 2023 - Springer
Immune dysregulation is a hallmark of clinically active multiple myeloma (MM). Interactions
between malignant clonal cells and immune cells within the bone marrow microenvironment …
between malignant clonal cells and immune cells within the bone marrow microenvironment …
Concomitant 1q+ and t (4; 14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
Dear editor, specific chromosomal abnormalities (CA) detected by Fluorescence in situ
hybridization (FISH), including translocation t (4; 14) and amplification or gain of …
hybridization (FISH), including translocation t (4; 14) and amplification or gain of …
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
X Mao, W Yan, D Mery, J Liu, H Fan… - American Journal of …, 2024 - Wiley Online Library
Current standard predictive models of disease risk do not adequately account for the
heterogeneity of survival outcomes in patients with new‐diagnosed multiple myeloma …
heterogeneity of survival outcomes in patients with new‐diagnosed multiple myeloma …